Publications by authors named "Chiara Ambrogio"

44Publications

Discoveries in the redox regulation of KRAS.

Int J Biochem Cell Biol 2021 Feb 10;131:105901. Epub 2020 Dec 10.

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article and Find Full Text PDF
February 2021

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.

Trends Cancer 2020 Dec 9. Epub 2020 Dec 9.

University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, 33600 Pessac, France. Electronic address:

View Article and Find Full Text PDF
December 2020

KRAS Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer.

Cancer Res 2020 09 30;80(17):3719-3731. Epub 2020 Jun 30.

Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.

View Article and Find Full Text PDF
September 2020

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.

EBioMedicine 2019 Nov 23;49:106-117. Epub 2019 Oct 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States. Electronic address:

View Article and Find Full Text PDF
November 2019

Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights.

Transl Lung Cancer Res 2018 Aug;7(4):487-497

Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.

View Article and Find Full Text PDF
August 2018

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

J Thorac Oncol 2018 08 6;13(8):e131-e133. Epub 2018 Apr 6.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article and Find Full Text PDF
August 2018

A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance.

Cell Adh Migr 2018 3;12(4):394-397. Epub 2018 Apr 3.

d University of Bordeaux , INSERM U1218, ACTION Laboratory, IECB , Pessac , France.

View Article and Find Full Text PDF
June 2019

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.

Cell 2018 02 11;172(4):857-868.e15. Epub 2018 Jan 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article and Find Full Text PDF
February 2018

A Braf kinase-inactive mutant induces lung adenocarcinoma.

Nature 2017 08 2;548(7666):239-243. Epub 2017 Aug 2.

Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain.

View Article and Find Full Text PDF
August 2017

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.

Cell Chem Biol 2017 Aug 3;24(8):1005-1016.e3. Epub 2017 Aug 3.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article and Find Full Text PDF
August 2017

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma.

Curr Med Chem 2018 Feb;25(5):558-574

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States.

View Article and Find Full Text PDF
February 2018

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy.

ESMO Open 2016 6;1(5):e000076. Epub 2016 Sep 6.

Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO) , Madrid , Spain.

View Article and Find Full Text PDF
September 2016

Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.

Blood 2016 Mar 8;127(10):1297-306. Epub 2016 Jan 8.

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Center for Experimental Medicine and Clinical Studies, University of Torino, Torino, Italy; Department of Pathology, Boston Children's Hospital, Boston, MA; and Harvard Medical School, Boston, MA.

View Article and Find Full Text PDF
March 2016